Kelly Marshall McNagny


Research Interests

Stem Cells
Mouse models of human disease
Tissue degeneration/regeneration
innate immune response
kidney function
Biologics and therapeutics

Relevant Degree Programs

Affiliations to Research Centres, Institutes & Clusters

Research Options

I am available and interested in collaborations (e.g. clusters, grants).
I am interested in and conduct interdisciplinary research.


Dr. Kelly McNagny obtained his Ph.D. in Cellular Immunology at the U. of Alabama at Birmingham in 1990. There he worked with Dr. Max D. Cooper (Howard Hughes Medical Institute, National Academy of Sciences) and his research focused on cell surface proteins expressed by preB cells that regulate B cell maturation and homing. He then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany where he performed his postdoctoral studies in the lab of Dr. Thomas Graf from 1991 to 1996. There his work focused on transcriptional control of hematopoietic stem cell maturation and cell fate. He performed some of the first studies to identify transcription factors that regulate the gene expression and differentiation of eosinophils, which are known to play a major role in allergic and asthmatic responses. In addition, he identified a number of novel hematopoietic stem cell surface proteins and began analyzing their function. He continued his studies at the EMBL as a semi-independent, Visiting Scientist from 1996 to 1998 prior to starting his own laboratory at The Biomedical Research Centre, at UBC where his currently a full professor in Medical Genetics and interim co-director of The BRC.

His laboratory has followed two primary interests: 1) the transcription factor networks that regulate fate determination in various cells that make blood, and 2) the cell surface proteins expressed by hematopoietic stem cells that and allow them to communicate with their microenvironment. In this regard, his lab has identified a novel family of hematopoietic cell surface proteins, called the CD34 family, and shown that these are essential for a number of developmentally important processes. Through gene knockout studies he has shown that these molecules act as a type of molecular “Teflon” to make cells more mobile and invasive and also facilitate chemotaxis. He has delineated the function of these molecules in diverse set of biological processes including: 1) gut and kidney formation, 2) vascular permeability, 3) mucosal inflammatory disease, 4) stem cell homing and migration, and 5) epithelial tumor progression.

Dr. McNagny has received a number of awards for his work at UBC including a CIHR Scholarship, a Michael Smith Foundation for Health Research Senior Scholarship and the 2002 Showell-Pfizer Junior Faculty Award from the American Association for Immunology. He is a member of the Stem Cell Network Centre of Excellence (past member of the Stem Cell Policy Committee and Research Management Committee and current Sub-chair of the Training and Education Committee), and a member of the AllerGen Network Centre of Excellence (Research Management Committee and Co-Chair of the Biomarkers Program).

Research Methodology

mouse models of inflammation
molecular biology
mutant mice
Flow cytometry
RNA sequencing


Doctoral students
Any time / year round
I support experiential learning experiences, such as internships and work placements, for my graduate students and Postdocs.
I am open to hosting Visiting International Research Students (non-degree, up to 12 months).

Complete these steps before you reach out to a faculty member!

Check requirements
  • Familiarize yourself with program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit the graduate degree program listing and program-specific websites.
  • Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study. This is either indicated in the program profile under "Admission Information & Requirements" - "Prepare Application" - "Supervision" or on the program website.
Focus your search
  • Identify specific faculty members who are conducting research in your specific area of interest.
  • Establish that your research interests align with the faculty member’s research interests.
    • Read up on the faculty members in the program and the research being conducted in the department.
    • Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
Make a good impression
  • Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
    • Do not send non-specific, mass emails to everyone in the department hoping for a match.
    • Address the faculty members by name. Your contact should be genuine rather than generic.
  • Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department. The supervision enquiry form guides you with targeted questions. Ensure to craft compelling answers to these questions.
  • Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to pique someone’s interest.
  • Demonstrate that you are familiar with their research:
    • Convey the specific ways you are a good fit for the program.
    • Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting.
  • Be enthusiastic, but don’t overdo it.
Attend an information session

G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.


Graduate Student Supervision

Doctoral Student Supervision (Jan 2008 - April 2022)
Generation, characterization and optimization of mouse models for genetic glomerular disease (2021)

Dominant and recessive mutations in podocalyxin (PODXL/Podxl) are associated with human kidney disease. Some PODXL/Podxl mutations manifest as anuria while others are associated with proteinuria. Homozygous loss-of-function mutations in the gene are associated with early-onset congenital nephrotic syndrome. By contrast, PODXL heterozygosity is associated with adult-onset kidney disease and podocalyxin shedding into the urine is a common biomarker of podocyte injury in various nephrotic contexts. It is unknown, however, how different lesions in PODXL/Podxl contribute to these disparate disease pathologies. Here we generated three mutant mouse stains: one that lacks Podxl in all tissues (Podxl-/-), a second that selectively deletes the gene in mature (capillary loop stage) podocytes (Podxl∆ᴾᵒᵈ), and a third that is heterozygous for Podxl in all tissues (Podxl⁺/-). We used histologic and ultrastructural analyses, as well as clinical chemistry assays to evaluate kidney development and function in these strains. In contrast to Podxl-/- mice, which have previously been shown to die 24 hours after birth from anuria and hypertension, we show that Podxl∆ᴾᵒᵈ mice develop an acute congenital nephrotic syndrome characterized by focal segmental glomerulosclerosis and severe proteinuria. Podxl⁺/- mice have a normal lifespan, and fail to develop kidney disease under normal conditions. Intriguingly, although wild-type C57Bl/6J mice are resistant to chemically-induced nephrosis, Podxl⁺/- mice are highly susceptible, as administration of puromycin aminonucleoside induces collapsing FSGS and nephrotic syndrome. The severity of kidney injury in Podxl⁺/- mice in response to puromycin aminonucleoside was optimized through dose-response experiments, and we used this model to evaluate the anti-proteinuric effects of the two calcineurin inhibitors, cyclosporine and voclosporin. Calcineurin inhibition by either voclosporin or cyclosporine did not attenuate proteinuria in Podxl⁺/- mice induced with puromycin aminonucleoside. In conclusion, we find that the developmental timepoint at which Podxl expression is ablated (immature vs. mature podocytes) has a profound impact on the renal disease phenotype due to its critical roles in both the formation and the maintenance of podocyte ultrastructure. In addition, Podxl∆ᴾᵒᵈ and Podxl⁺/- mice offer powerful new tools to evaluate early biomarkers of proteinuric kidney disease, to define the function of genes during kidney injury, and to test new therapies.

View record

Investigation of the role of podocalyxin in cancer progression and its potential as a cancer therapeutic (2021)

The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last three decades, however, cancer still remains the second leading cause of death worldwide. Importantly, the majority of cancer-related deaths are the result of metastatic disease. This highlights the need to identify biomarkers of tumors at high risk of metastasizing, and to generate targeted therapies against them. Previous studies have demonstrated a strong association between high expression of podocalyxin and decreased patient survival, however, little is known about the role of podocalyxin in promoting cancer progression or its potential as a therapeutic target.Here we perform an in-depth characterization of PODO83, an anti-podocalyxin antibody that we previously demonstrated delays primary tumor growth in murine tumor models. We show that despite its ability to delay primary tumor growth, its primary effect is actually the prevention of metastasis to the lung. We identified the binding epitope of PODO83 on the extracellular juxtamembrane domain of podocalyxin and showed that the antibody recognizes the core podocalyxin protein in both tumors and healthy tissue. Further, using urothelial, breast and ovarian carcinomas tissue microarrays, we present PODO83 as a promising diagnostic tool.Podocalyxin is normally readily expressed in the vascular endothelia and kidney podocytes, representing a source of concern surrounding the use of podocalyxin-based therapies. Here, we identified a novel tumor-restricted glycoepitope on podocalyxin and generated and characterized an antibody (PODO447) to target it. We found that while unconjugated PODO447 does not exert any inhibitory or toxic effect on tumor cells, when used as the targeting arm in a Vedotin antibody-drug conjugate (ADC), the PODO447-ADC specifically targets cancerous cells and increases the survival in pre-clinical models. The work presented in this thesis contributes directly to scientific understanding of the role of podocalyxin in tumor growth and metastasis. Further, we provide pre-clinical evidence supporting the furthered development of the novel podocalyxin antibodies PODO83, and PODO447 as diagnostic and targeted immunotherapies, respectively, to be used in the fight against cancer and to improve patient outcome.

View record

The role of ROR alpha and CD34 in mucosal inflammation and fibrosis (2017)

Fibrosis is the result of dysregulated tissue regeneration and is characterized by excessive accumulation of matrix proteins that become detrimental to tissue function. Type 2 immunity has long been associated with fibrotic scarring because of its role in wound healing and parasite-initiated tissue remodeling. Our objective was to examine two components of this inflammatory pathway that could potentially be modulated to limit fibrosis, namely RORα, a nuclear receptor required for ILC2 development, and CD34, a sialomucin involved in trafficking of eosinophils and mast cells to peripheral tissues. Using a model of infection-induced chronic gut inflammation, we demonstrate that Rora-deficient mice are protected from fibrosis; infected intestinal tissues displayed diminished pathology and attenuated collagen deposition. Although Rora is known for its role in ILC2s, we found that Salmonella-induced fibrosis was independent of eosinophils, STAT6 signaling and Th2 cytokines arguing that ILC2s are dispensable in this disease model. Instead, we observed reduced levels of ILC3- and T cell-derived IL-17A and IL-22 in infected tissues. Furthermore, using Rorasg/sg/Rag1-/- bone marrow chimeric mice, we found that restoring ILC function was sufficient to re-establish IL-17A and IL-22 production and a profibrotic phenotype. Our findings suggest that RORα-dependent ILC3 functions are pivotal in mediating gut fibrosis and they offer an avenue for therapeutic intervention in Crohn’s-like diseases. CD34 has been shown to drive lung inflammation and colitis by coordinating immune cell recruitment. However CD34 is also expressed by multiple non-hematopoietic subsets including endothelial and mesenchymal cells. To assess CD34 function in pulmonary repair, we induced lung injury by bleomycin administration. We found that Cd34-/- mice displayed severe weight loss and early mortality compared to WT controls. CD34-deficient animals developed severe interstitial edema and endothelial delamination, indicating impaired endothelial function. Chimeric Cd34-/- mice reconstituted with WT hematopoietic cells exhibited early mortality compared to WT mice reconstituted with Cd34-/- cells thus confirming this to be a non-hematopoietic defect. Lastly, CD34-deficient mice were more sensitive to lung damage caused by influenza infection, displaying greater weight loss and more extensive pulmonary remodeling. These results suggest that CD34 plays a protective role in maintaining vascular integrity in response to lung damage.

View record

Role of Group 2 Innate Lymphoid Cells and SHIP-1 in Mucosal Immunity (2015)

Mucosal surfaces present an important barrier between the host and environment. Maintenance of barrier function requires intricate cross-talk between a diverse array of immune cells and the epithelia, acting synergistically to respond to harmful antigens and maintain tolerance to innocuous antigens. In this thesis I utilized an array of transgenic animals to explore the cellular and molecular mechanisms that initiate adaptive immune responses in the lung and gut mucosa.Recently, innate lymphoid cells have been characterized for their role in maintaining barrier immunity. Group 2 innate lymphoid cells (ILC2s) colonize the lung and provide a rapid source of IL-5 and IL-13 in a T and B cell independent manner in response to protease antigens. Using ILC2-deficient mice, I examined the role of these cells in mucosal inflammation using mouse models of allergic asthma and hypersensitivity pneumonitis (HP). ILC2s were critical in initiation of a Th2 response to locally, but not systemically delivered allergens and were completely dispensable for Th1 and Th17 dependent responses. The PI3K pathway plays an important role in regulating leukocyte activation, survival, migration and cytokine release. It is negatively regulated by the lipid phosphatase Ship1, and Ship1-/- mice develop a wide array of hematological disorders leading to a reduced lifespan. The severe phenotype associated with loss of Ship1 throughout the immune systems masks subtler roles it plays in specific leukocyte subsets. Using a conditional deletion approach, I examined the role of Ship1 in T cells, B cells and dendritic cells (DCs) in mouse models of allergic asthma and helminth infection. While loss of Ship1 in B cells did not influence susceptibility to a HDM model of allergic asthma, loss of Ship1 in either the T cells or DCs protected from disease development due to an immune skewing to a Th1 response. Additionally, loss of Ship1 in DCs rendered mice susceptible to infection with the intestinal helminth Trichuris muris, further highlighting this Th1 immune skewing.

View record

The Structural and Functional Importance of the CD34 Family in Lung Function and Vascular Cell Biology (2012)

Despite the widespread use of CD34-family sialomucins (CD34, podocalyxin (Podxl) andendoglycan) as vascular endothelial cell (EC) markers, there is remarkably little known oftheir role in vascular development and functions with the exception of vessel lumenformation in the developing mouse embryo (Podxl) and vessel patency during tumorangiogenesis and inflammation (CD34). Because germ-line deletion of Podxl in mice causesperinatal death, we generated mice that conditionally delete Podxl in vascular endothelialcells (PodxlΔEC mice) to study the role of podocalyxin in adult mouse vessels. AlthoughPodxlΔEC adult mice are viable and thrive, we discovered increased basal and inflammationinducedpulmonary vascular permeability. Furthermore, PodxlΔEC mouse adult lungs displayairspace enlargement with increased collagen deposition and exhibit a gene expressionprofile similar to regenerating lung. To study whether endothelial cell morphology influencesthe defective lung architecture and the vascular permeability phenotype in PodxlΔEC mice, weisolated primary vascular ECs from lung tissue. PodxlΔEC ECs display enhanced adhesion tofibronectin (FN) in a static adhesion assay. When plated on matrix-coated transwells,PodxlΔEC EC spread normally on FN but display defective spreading on laminin and collagenI. Thus, expression of Podxl in EC is required for normal lung architecture and function inadult mice and adhesion of EC to extracellular matrix components.Although its expression has not been well characterized, in humans, endoglycan expressionhas been reported in vascularized tissues. In mouse blood vessels, we showed that vascularsmooth muscle cells (vSMC), but not EC, express the highest levels of endoglycan. Using amouse aortic smooth muscle line (MOVAS-1) we found that forced expression ofendoglycan enhances basal but not platelet derived growth factor (PDGF)ββ-dependentvSMC migration in vitro. Further studies to understand the role of endoglycan in primaryvSMC showed that endoglycan is upregulated with differentiation to a contractile phenotype,but is not influenced by inflammatory stimuli or mitogenic factors. The findings of this thesis suggest that the CD34 family regulates vascular development andfunction with a role for podocalyxin in EC-matrix adhesion relevant to normal lung functionand a role for endoglycan in SMC differentiation and migration.

View record

The role of podocalyxin and CD34 in mouse models of anemia, asthma, ulcerative colitis and tumor growth (2010)

No abstract available.

Mast cells : homeostatic regulation, activation, gene expression, surface antigens, and role in allergic disease (2009)

Overall, we aimed to discover more about mast cell physiology, focusing on their homeostatic regulation in vivo, their activation in vitro and in allergic disease, their gene expression patterns, and their surface antigens. In our first study, our objective was to establish the function of Src homology 2-containing inositol 5’-phosphatase (SHIPI), in mast cells in vivo. SHIP1 inhibits immune receptor signaling throughhydrolysis of the phosphatidylinositol-3 kinase (P13K) product Pl-3,4,5-P₃ ,forming P1-3,4-P₂. In mast cells, SHIPI represses FcεRI- and cytokine-mediated activation in vitro, but little is known regarding the function of SHIPI in mast cells in vivo, or the susceptibility of Shipl⁻/⁻ mice to mast cell-associated diseases. We found that ⁻ mice have systemic mast cell hyperplasia, increased serum levels of IL-6, TNF, and IL-5, and a heightened anaphylactic response. Further, by reconstituting mast cell-deficient mice with Ship1⁺/⁺ or Shipl⁻/⁻ mast cells, we found that the above defects were due to loss of SHIPI in mast cells. Additionally, we found that micereconstituted with Shipl⁻/⁻ mast cells suffered worse allergic asthma pathology than those reconstituted with Ship1⁺/⁺ mast cells. In summary, our data show that SHIPI represses allergic inflammation and mast cell hyperplasia in vivo, and that SHIPI exerts these effects specifically in mast cells. In our second study we compared Lin⁻Sca-1⁺c-kit⁺ (LSK) cells, which are highlyenriched for hematopoietic stem cells (HSC), and mast cells, using microarray expression analysis, and identified prion protein (PrPC) as a potentially novel marker of mast cells. Upon further investigation, we found that PrPC (1) is expressed on the surface of human and mouse mast cells, both in vitro and in vivo; (2) is not required for mast cell differentiation or tissue homeostasis; (3) is released by mast cells atsteady state and rapidly upon activation; and (4) is released in response to mast cell dependent allergic inflammation in vivo. Since mast cells are long-lived and known to traffic to the brain and central nervous system (CNS), our observations could have important implications for the transmission and pathology of prion diseases. Further, mast cells could be a unique system to investigate PrPc’s normal function.

View record

Role of podocalyxin in hematopoiesis and cell migration (2008)

CD34 and its relatives, Podocalyxin and Endoglycan, comprise of a family ofsurface sialomucins expressed by hematopoietic stem/progenitor cells, and vascularendothelia. Recent data suggest that they serve as either pro- or anti-adhesion moleculesdepending on their cellular context and their post-translational modifications. We wereinterested in identifying Podocalyxin ligands and their cellular distribution andunderstanding the role of these factors in signaling, adhesion and migration. Using both alambda phage screen assay and mass spectrometry, we identified the Na⁺/H⁺ exchangerregulatory factor-i (NHERF-l) as a selective ligand for Podocalyxin and Endoglycan butnot for the closely related CD34. Furthermore, we showed that NHERF-1 is expressedby all, lineage⁻, Sca-1⁺ and c-kit⁺ (LSK) cells, which are known to express Podocalyxinand have long-term repopulating characteristics of hematopoietic stem cells. In addition,upon IL-3 stimulation of a factor dependent cell line (FDC-P 1) these proteins re-localizeand co-localize in an asymmetrical pattern. By using a lentiviral based shRNA system tosilence Podocalyxin and NHERF- i proteins, we observed that migration across stromalmonolayer towards a CXCL12 and SCF gradient is significantly impeded in cells thatlack Podocalyxin but not NHERF-1. Following in vitro stimulation with a combinationof CXCL12 and SCF we observed that Podocalyxin co-associates with CXCR4.Furthermore, cells lacking Podocalyxin have decreased phospho-AKT, a key signalingmolecule downstream of c-kit and CXCR4 receptors. Taken together, our data supportsthe conclusion that Podocalyxin co-association with CXCR4 modulates downstreamsignaling to efficiently regulate HSC homing.

View record

Master's Student Supervision (2010 - 2021)
Re-evaluating the origins of group 2 innate lymphoid cells through the lens of T-cell development (2021)

The discovery of innate lymphoid cells (ILCs) has revolutionized our understanding of innate immunity and immune cell interactions at epithelial barrier sites. Their presence and maintenance are critical for modulating immune homeostasis, responding to injury or infection, and repairing damaged tissues. ILCs are remarkably similar to CD4+ T helper subsets in terms of function and transcription factors required for their development but are distinguished by their lack of antigen specific receptors. Despite their similarities, the absence of a surface TCR and presence of ILCs/precursors in adult bone marrow has led to speculation that ILCs and T cells develop separately from lineages that branch at the point of precursors within the bone marrow. Considering the common lineage markers and effector cytokine profiles shared between ILCs and T cells, it is surprising that the status of the TCR loci in ILCs was not fully explored at the time of their discovery. In this thesis, we demonstrate that a high proportion of peripheral tissue ILC2s have TCRγ chain gene rearrangements and TCRδ locus deletions. Detailed analyses of these loci show abundant frameshifts and premature stop codons that would encode non- functional TCR proteins. Collectively, these data argue that ILC2 can develop from T cells that fail to appropriately rearrange TCR genes, potentially within the thymus.

View record

Podocalyxin promotes vascular barrier function (2018)

The CD34-family sialomucin, podocalyxin (Podxl), is broadly expressed on the luminal face of blood vessels in adult mammals; however, its biological function on vascular endothelial cells (vEC) is not well-defined. Here, we reveal specific functions for podocalyxin in maintaining endothelial barriers using HUVEC monolayers as a model in vitro. Detailed analysis of barrier HUVEC characteristics using electrical cell-substrate impedance sensing (ECIS) and live cell imaging revealed essential roles for podocalyxin in maintaining cell-cell and cell-matrix interactions. Thus, podocalyxin-deficient HUVEC fail to form a functional barrier when plated on several extracellular matrix (ECM) substrates. Regardless of ECM substrate, these monolayers lack adherens junctions and focal adhesions; and display a disorganized cortical actin cytoskeleton. To explore an in vivo function of podocalyxin, we conditionally deleted Podxl in vEC using the Tie2Cre strain (PodxlΔTie2Cre). Although we did not detect altered permeability in naïve mice at steady state, systemic priming with lipopolysaccharides (LPS) disrupted the blood-brain barrier (BBB) in PodxlΔTie2Cre but not WT mice. To study the potential consequence of this BBB breach, we used a selective agonist of PAR-1, a thrombin receptor expressed by neurons and glial cells. As a polar peptide, the PAR-1 agonist (TFLLRN), is normally excluded from CNS parenchyma by the BBB. In response to systemic administration of TFLLRN, LPS-primed PodxlΔTie2Cre mice experienced a dramatic behavioral change marked by a severely dampened neurological electrical activity. We conclude that podocalyxin expression by CNS vECs is required to maintain BBB integrity under inflammatory conditions. Supplementary materials available at:

View record

The role of podocalyxin in breast cancer progression and metasasis (2014)

The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. While many breast tumors are curable surgically, others have an increased tendency to relapse or metastasize. Podocalyxin (gene name PODXL) is a CD34-related sialomucin that is important in regulating cell adhesion, migration, and polarity of hematopoietic progenitors and vascular endothelia. Previously, podocalyxin expression in primary breast tumor cells has been correlatively linked to poor patient survival. In addition, overexpression of podocalyxin in MCF-7 luminal breast cancer cells results in an overall increase in aggressive morphological features including: apical bulging, microvillus formation, and disrupted integrin targeting to the basolateral surface. To determine whether podocalyxin has a definitive role in breast tumor progression, I used shRNA-based vectors to silence expression of PODXL in a basal-like breast cancer cell-line, MDA.MB-231, which normally expresses high levels of endogenous podocalyxin, forms poorly polarized monolayers and tumorspheres in vitro and rapidly forms metastatic tumors in vivo. I found that podocalyxin impairs adhesion to extracellular matrices (ECM) and is critical for the formation of tumorspheres in vitro. In addition, I found that podocalyxin expression is critical for both primary tumor development and the formation of distant metastases in the lung, liver, and bone marrow in xenografted mice. These findings were corroborated by use of a mouse mammary tumor cell line (4T1) in a syngeneic model of metastatic tumor progression.Furthermore, in collaboration with the Centre for Drug Research and Development (UBC), I evaluated the ability of candidate therapeutic antibodies to podocalyxin to block the growth and metastasis of established tumors. One candidate antibody, known as anti-PODO, was found to significantly inhibit primary tumorigenesis in a pre-clinical mouse model. In summary, in this thesis I demonstrate for the first time that podocalyxin plays a causal role in promoting the growth of solid tumors and enhancing metastasis of tumor cells to distant organs. These findings have the potential to improve treatments for breast cancer patients by providing a highly specific and well-tolerated adjuvant therapy for metastatic disease.

View record

The role of SHIP1 in modulating disease severity in the K/BxN serum transfer model of rheumatoid arthritis (2011)

SHIP1 (SH2 domain containing inositol-5ʼ-phosphatase) is a negative regulator of thephosphatidylinositol-3 kinase (PI3K) pathway. SHIP1 is expressed in hematopoietic cells,and mediates its effect by hydrolyzing PIP₃, an important second messenger generated bythe PI3K pathway. In this way, SHIP attenuates a variety of signaling cascades includingthose mediating cell survival and proliferation. Due to its importance in regulating immunecell signaling, SHIP1 is an attractive therapeutic target.In this thesis, I explored the role of SHIP1 in the context of rheumatoid arthritis, anautoimmune inflammatory disease. To this end, I employed the K/BxN serum transfer modelof rheumatoid arthritis. This disease model is auto-antibody driven and lymphocyteindependent, and thus facilitates characterization of the effector phase of disease, a processthat relies on components of the innate immune system. Arthritis was dramaticallyexacerbated in global SHIP1 knock-out mice, as evidenced by changes in ankle thickness,clinical scoring and histological analysis. Heterozygous SHIP1 mice also displayedincreased disease severity in comparison to wild type litter mates, possibly due to anexpanded population of circulating neutrophils, that increases with age. Since naive globalSHIP1 knock-out mice exhibit a range of hematopoietic abnormalities, to elucidate the cellintrinsic contribution of SHIP1 ablation to the disease phenotype, I induced K/BxN mediatedarthritis in mice with lineage restricted deletion of SHIP1. Mice with a neutrophil/macrophage-restricted loss of SHIP1 (LysMcre), like global SHIP1 knock-out mice,displayed an alternatively activated ʻM2ʼ biased macrophage phenotype, and developedexacerbated disease. Neutrophil-restricted loss of SHIP1 (GEcre) was also sufficient toexacerbate disease and resulted in earlier disease onset. In order to identify how the loss ofSHIP1 in neutrophils results in heightened disease severity, I performed a series of in vitroexperiments utilizing polymorphonuclear leukocytes freshly isolated from bone marrow.While we cannot exclude that SHIP1 may be playing additional roles in neutrophil functions,I report that SHIP1 plays a role in attenuating responsiveness of neutrophils to GPCR andFcγR ligation, two families of receptors that are necessary for induction and amplification ofrheumatoid arthritis in the K/BxN serum transfer model.

View record


  • IQCELL: A platform for predicting the effect of gene perturbations on developmental trajectories using single-cell RNA-seq data (2022)
    PLOS Computational Biology, 18 (2), e1009907
  • Inflammation-Induced Metastatic Colonization of the Lung Is Facilitated by Hepatocyte Growth Factor-Secreting Monocyte-Derived Macrophages (2021)
    Molecular Cancer Research,
  • Group 2 Innate Lymphoid Cells: Central Players in a Recurring Theme of Repair and Regeneration (2020)
    International Journal of Molecular Sciences, 21 (4), 1350
  • Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease (2019)
    Scientific Reports, 9 (1)
  • IL-22 Preserves Gut Epithelial Integrity and Promotes Disease Remission during Chronic Salmonella Infection (2019)
    The Journal of Immunology, 202 (3), 956--965
  • The first identified heterozygous nonsense mutations in podocalyxin offer new perspectives on the biology of podocytopathies (2019)
    Clinical Science, 133 (3), 443--447
  • The Transcription Factor RORα Preserves ILC3 Lineage Identity and Function during Chronic Intestinal Infection (2019)
    The Journal of Immunology, , ji1900781
  • Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner (2018)
    Proceedings of the National Academy of Sciences, 115 (7), 1588--1592
  • Mast Cells in Human Health and Disease (2015)
    , 93--119
  • Measurement of Mast Cell Surface Molecules BY High-Throughput Immunophenotyping Using Transcription (HIT) (2015)
    , 381--400
  • Genes, the environment and personalized medicine (2014)
    EMBO reports,
  • Group 2 innate lymphoid cells Are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation (2014)
    Immunity, 40 (3), 425--435
  • Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, T< sub> H 2-inducing allergen exposures (2014)
    Journal of Allergy and Clinical Immunology, 133 (4), 1142--1148
  • ILC2+ DC= Th2, group 2 innate lymphoid cell derived IL-13 is essential for efficient T helper 2 cell differentiation in allergic lung inflammation.(HYP6P. 258) (2014)
    The Journal of Immunology, 192 (1 Sup), 118--3
  • Impairing Eukaryotic Elongation Factor 2 Kinase (eEF2K) Activity Decreases Atherosclerotic Plaque Formation (2014)
    Canadian Journal of Cardiology,
  • Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation (2014)
    Can J Cardiol, 30 (12), 1684-8
  • Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation (2014)
    The Journal of clinical investigation, 124 (5), 0--0
  • Mutant Mice and Animal Models of Airway Allergic Disease (2014)
    , 295--308
  • Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases (2014)
    Journal of Allergy and Clinical Immunology,
  • Podocalyxin Regulates Murine Lung Vascular Permeability by Altering Endothelial Cell Adhesion (2014)
    PloS one, 9 (10), e108881
  • The NLRP3 Inflammasome/IL-1RI Axis Mediates Innate Immune but Not Adaptive Immune Responses Following PM10 Exposure (2014)
    American journal of respiratory cell and molecular biology, (ja)
  • A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue (2013)
    World journal of stem cells, 5 (1), 1
  • Enu Mutagenesis Identifies a Novel Platelet Phenotype in a Loss-Of-Function Jak2 Allele (2013)
    PloS one, 8 (9), e75472
  • Granzyme B Deficiency Exacerbates Lung Inflammation in Mice after Acute Lung Injury (2013)
    American journal of respiratory cell and molecular biology, 49 (3), 453--462
  • Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma (2013)
    Gut Microbes, 4 (2), 158--164
  • Perinatal Immunization With Vaccine-Grade Listeria monocytogenes Provides Protection Against Murine Th2 Airway Inflammation (2013)
    Allergy, Asthma & Immunology Research, 6
  • Requirement for core 2 o-glycans for optimal resistance to helminth infection (2013)
    PloS one, 8 (3), e60124
  • SIGIRR, a negative regulator of TLR/IL-1R signalling promotes Microbiota dependent resistance to colonization by enteric bacterial pathogens (2013)
    PLoS pathogens, 9 (8), e1003539
  • Analysis of the mobilities of band 3 populations associated with ankyrin protein and junctional complexes in intact murine erythrocytes (2012)
    Journal of Biological Chemistry, 287 (6), 4129--4138
  • Cytopenia induction by 5-fluorouracil identifies thrombopoietic mutants in sensitized ENU mutagenesis screens (2012)
    Experimental hematology, 40 (1), 48--60
  • Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma (2012)
    EMBO reports, 13 (5), 440--447
  • IL-7R\$α\$ and L-selectin, but not CD103 or CD34, are required for murine peanut-induced anaphylaxis (2012)
    Allergy, Asthma \& Clinical Immunology, 8 (1), 15
  • IL-7R$α$ and L-selectin, but not CD103 or CD34, are required for murine peanut-induced anaphylaxis (2012)
    Allergy, Asthma & Clinical Immunology, 8 (1), 15
  • Mouse models to evaluate the function of genes associated with allergic airway disease (2012)
    Current opinion in allergy and clinical immunology, 12 (5), 467--474
  • Myeloid cell-specific expression of Ship1 regulates IL-12 production and immunity to helminth infection (2012)
    Mucosal immunology,
  • Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation (2012)
    Immunity, 37 (3), 463--474
  • The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma (2012)
    Clinical & experimental metastasis, 29 (3), 239--252
  • A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis (2011)
    Experimental hematology, 39 (3), 305--320
  • CD34 is required for dendritic cell trafficking and pathology in murine hypersensitivity pneumonitis (2011)
    American journal of respiratory and critical care medicine, 184 (6), 687--698
  • CD34 promotes satellite cell motility and entry into proliferation to facilitate efficient skeletal muscle regeneration (2011)
    Stem cells, 29 (12), 2030--2041
  • Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool (2011)
    Nature neuroscience, 14 (9), 1142--1149
  • NUP98-HOXA10hd-expanded hematopoietic stem cells efficiently reconstitute bone marrow of mismatched recipients and induce tolerance (2011)
    Cell transplantation, 20 (7), 1099--1108
  • Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration (2011)
    PloS one, 6 (4), e18160
  • SHIP represses Th2 skewing by inhibiting IL-4 production from basophils (2011)
    The Journal of Immunology, 186 (1), 323--332
  • Adhesion molecules in experimental peanut allergy (2010)
    Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clinical Immunology, 6 (Suppl), P10
  • CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis (2010)
    The American journal of pathology, 177 (3), 1244--1254
  • CD34 mediates intestinal inflammation in Salmonella-infected mice (2010)
    Cellular microbiology, 12 (11), 1562--1575
  • Communication-The changing landscape of human--animal chimera research: A Canadian regulatory perspective (2010)
    Stem cell research, 4 (1), 10--16
  • Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling (2010)
    Gastroenterology, 139 (4), 1277--1288
  • Loss of CD34 leads to exacerbated autoimmune arthritis through increased vascular permeability (2010)
    The journal of immunology, 184 (3), 1292--1299
  • Myh9 (Q1443L) Is a Novel Mouse Model of MYH9-Related Disorders. (2010)
    116 (21), 1047--1048
  • Podocalyxin is a novel polysialylated neural adhesion protein with multiple roles in neural development and synapse formation (2010)
    PloS one, 5 (8), e12003
  • The metalloprotease-disintegrin ADAM8 is essential for the development of experimental asthma (2010)
    American journal of respiratory and critical care medicine, 181 (12), 1318--1328
  • Allergy, Asthma \& Clinical Immunology (2009)
  • Allergy, Asthma & Clinical Immunology (2009)
  • Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis (2009)
    The Journal of Immunology, 182 (9), 5507--5514
  • CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery (2009)
    Microcirculation, 16 (6), 487--496
  • CD34 Mediates Dendritic Cell Trafficking in Hypersensitivity Pneumonitis. (2009)
    Am J Respir Crit Care Med, 179, A4284
  • iPS cells: mapping the policy issues (2009)
    Cell, 139 (6), 1032--1037
  • Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation (2009)
    Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1796 (1), 19--26
  • Podocalyxin selectively marks erythroid-committed progenitors during anemic stress but is dispensable for efficient recovery (2009)
    Experimental hematology, 37 (1), 10--18
  • Prion protein expression and release by mast cells after activation (2009)
    Journal of Infectious Diseases, 200 (5), 827--831
  • SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo (2009)
    The Journal of Immunology, 183 (1), 228--236
  • The molecular basis of vascular lumen formation in the developing mouse aorta (2009)
    Developmental cell, 17 (4), 505--515
  • The Rap GTPases regulate the migration, invasiveness and in vivo dissemination of B-cell lymphomas (2009)
    Oncogene, 29 (4), 608--615
  • The role of podocalyxin in health and disease (2009)
    Journal of the American Society of Nephrology, 20 (8), 1669--1676
  • Novel functions of the CD34 family (2008)
    Journal of Cell Science, 121 (22), 3683--3692
  • The lung responds to zymosan in a unique manner independent of toll-like receptors, complement, and dectin-1 (2008)
    American journal of respiratory cell and molecular biology, 38 (2), 227--238
  • CD34 facilitates the development of allergic asthma (2007)
    Blood, 110 (6), 2005--2012
  • Influence of host irradiation on long-term engraftment by CD34-deficient hematopoietic stem cells (2007)
    Blood, 110 (3), 1076--1077
  • Mast cells are an essential hematopoietic component for polyp development (2007)
    Proceedings of the National Academy of Sciences, 104 (50), 19977--19982
  • The CD34-related molecule podocalyxin is a potent inducer of microvillus formation (2007)
    PLoS One, 2 (2), e237
  • Beyond mere markers (2006)
    Immunologic research, 34 (1), 13--32
  • Hematopoietic stem cells do not engraft with absolute efficiencies (2006)
    Blood, 107 (2), 501--507
  • Na+/H+ Exchanger Regulatory Factor-1 Is a Hematopoietic Ligand for a Subset of the CD34 Family of Stem Cell Surface Proteins (2006)
    Stem Cells, 24 (5), 1150--1161
  • CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution (2005)
    Immunity, 22 (1), 43--57
  • CD34 expression by mast cells: of mice and men (2005)
    Blood, 106 (5), 1885--1887
  • Pattern of expression of the podocalyxin gene in the mouse brain during development (2005)
    Gene expression patterns, 5 (3), 349--354
  • Platelets express functional Toll-like receptor-4 (2005)
    Blood, 106 (7), 2417--2423
  • Podocalyxin A marker of blasts in acute leukemia (2005)
    American journal of clinical pathology, 124 (1), 134--142
  • Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells (2005)
    Blood, 105 (11), 4170--4178
  • Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression (2004)
    Cancer research, 64 (15), 5068--5073
  • E26 leukemia virus converts primitive erythroid cells into cycling multilineage progenitors (2003)
    Blood, 101 (3), 1103--1110
  • Avian models to study the transcriptional control of hematopoietic lineage commitment and to identify lineage-specific genes (2002)
    Cells Tissues Organs, 171 (1), 44--63
  • CD34 is a specific marker of mature murine mast cells (2002)
    Experimental hematology, 30 (10), 1211--1218
  • Making eosinophils through subtle shifts in transcription factor expression (2002)
    The Journal of experimental medicine, 195 (11), F43--F47
  • The v-erbA oncogene blocks expression of alpha2/beta1 integrin a normal inhibitor of erythroid progenitor proliferation. (2002)
    Oncogene, 21 (18), 2864--2872
  • Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin (2001)
    The Journal of experimental medicine, 194 (1), 13--28
  • Surface molecules involved in avian T-cell progenitor migration and differentiation (2000)
    Developmental immunology, 7 (2-4), 267
  • Characterization of prethymic progenitors within the chicken embryo (1999)
    International immunology, 11 (1), 63--69
  • Distinct C/EBP functions are required for eosinophil lineage commitment and maturation (1998)
    Genes & development, 12 (15), 2413--2423
  • Regulation of eosinophil-specific gene expression by a C/EBP--Ets complex and GATA-1 (1998)
    The EMBO Journal, 17 (13), 3669--3680
  • Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors (1997)
    The Journal of cell biology, 138 (6), 1395--1407
  • Acute avian leukemia viruses as tools to study hematopoietic cell differentiation (1996)
    , 143--162
  • Excision of Ets by an inducible site-specific recombinase causes differentiation of Myb--Ets-transformed hematopoietic progenitors (1996)
    Current Biology, 6 (7), 866--872
  • HEMCAM, an adhesion molecule expressed by c-kit+ hemopoietic progenitors. (1996)
    The Journal of cell biology, 135 (6), 1655--1668
  • The eosinophil-specific cell surface antigen, EOS47, is a chicken homologue of the oncofetal antigen melanotransferrin (1996)
    Blood, 87 (4), 1343--1352
  • Integrin alpha 2 beta 1 mediates interactions between developing embryonic retinal cells and collagen (1995)
    Development, 121 (11), 3593--3602
  • v-Myb DNA binding is required to block thrombocytic differentiation of Myb-Ets-transformed multipotent haematopoietic progenitors. (1995)
    The EMBO journal, 14 (12), 2866
  • A functional Ets DNA-binding domain is required to maintain multipotency of hematopoietic progenitors transformed by Myb-Ets. (1994)
    Genes & development, 8 (1), 33--44
  • Cell surface proteins of chicken hematopoietic progenitors, thrombocytes and eosinophils detected by novel monoclonal antibodies. (1992)
    Leukemia, 6 (10), 975--984
  • Chicken “erythroid” cells transformed by the Gag-Myb-Ets-encoding E26 leukemia virus are multipotent (1992)
    Cell, 70 (2), 201--213
  • Reticular cells in peripheral lymphoid tissues express the phosphatidylinositol-linked BP-3 antigen (1991)
    European journal of immunology, 21 (2), 509--515
  • BP-3 alloantigen. A cell surface glycoprotein that marks early B lineage cells and mature myeloid lineage cells in mice. (1988)
    The Journal of Immunology, 141 (8), 2551--2556

If this is your researcher profile you can log in to the Faculty & Staff portal to update your details and provide recruitment preferences.


Follow these steps to apply to UBC Graduate School!